Teva UK Limited has welcomed recent clinical guidelines from the National Institute for Health and Clinical Excellence (NICE) on the use of strong opioids for pain in adult palliative care.
The guidelines identified that patients in the UK are often under-treated for pain, particularly that resulting from advanced disease.
Robyn Hughes, Director of Brands at Teva, said: “We welcome any recommendations that aim to improve patient care, and are pleased that the under-treatment of pain in the UK has been recognised.”
“Patients are individuals, and – from working with leading healthcare professionals in palliative care – we believe there should be a personalised medicines approach rather than a one size fits all option driven by standard cost-based protocols. We’re pleased the new guidelines recognise the different drug types that are available to treat pain, and we look forward to working with the NHS in implementing the new guidelines, to help improve the lives of UK patients.”
Teva is one of the UK’s leading pharmaceutical companies, and offers a comprehensive portfolio of pain products covering first- , second- and third-line treatments, all marketed under its new Pain Care franchise. Many of these products were previously marketed by Cephalon, and are now in Teva’s portfolio following the Company’s acquisition of Cephalon in 2011.
- NICE clinical guideline 140: Opioids in palliative care: safe and effective prescribing of strong opioids for pain in palliative care of adults, May 2012. (www.guidance.nice.org.uk/cg140)
About Teva UK Limited’s Pain Care range
Find out more about Teva UK Limited’s Pain Care range (content for healthcare professionals only).